Swart, Maarten http://orcid.org/0000-0001-6109-0773
Kuipers, Harmjan http://orcid.org/0000-0003-1317-394X
Milder, Fin
Jongeneelen, Mandy
Ritschel, Tina
Tolboom, Jeroen
Muchene, Leacky
van der Lubbe, Joan http://orcid.org/0000-0002-9609-5539
Izquierdo Gil, Ana http://orcid.org/0000-0001-9557-1807
Veldman, Daniel
Huizingh, Jeroen
Verspuij, Johan
Schmit-Tillemans, Sonja
Blokland, Sven
de Man, Martijn
Roozendaal, Ramon http://orcid.org/0000-0002-4084-4801
Fox, Christopher B. http://orcid.org/0000-0002-4644-2619
Schuitemaker, Hanneke http://orcid.org/0000-0001-8563-2266
Capelle, Martinus
Langedijk, Johannes P. M. http://orcid.org/0000-0001-8768-0982
Zahn, Roland http://orcid.org/0000-0003-2822-6231
Brandenburg, Boerries
Funding for this research was provided by:
U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (HHSO100201700018C)
Article History
Received: 8 June 2023
Accepted: 2 November 2023
First Online: 11 November 2023
Competing interests
: J.P.M.L., F.M., M.J., T.R., and B.B. are an inventor on patents or patent applications related to H1 stem v2. C.B.F. is an inventor on patents or patent applications related to the SLA-LSQ adjuvant formulation. The other authors were employees of Janssen Pharmaceutical Companies of Johnson & Johnson at the time of the study and may have ownership of shares in Janssen Pharmaceutical Companies of Johnson & Johnson. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Department of Health and Human Services or its components.